Researchers are exploring the use of human disease models, including organ chips and brain organoids, to improve drug development. These models may potentially reduce the need for animal testing, such as using mice, and enable more precise and human-relevant pre-clinical testing. The development and scaling of these human-derived models is seen as a significant opportunity for advancing drug discovery.